Sanofi Cleans House, Cuts Assets from Principia and Ablynx Buyouts

FDA Adcomm Backs Accelerated Approval of Biogen’s Tofersen in SOD1-ALS

[{"selector":"#anim-c35e2ef7-b046-4787-8343-fbcb3f95e48d","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1f7a3a82-b4eb-4ad9-870c-fd3c130dc718","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

1. Sanofi is discontinuing two acquired programs as part of its pipeline restructuring.

[{"selector":"#anim-a12386cf-0185-4819-b5be-34fa310e1987","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

2. Atuzabrutinib from Principia is being dropped due to efficacy and pharmacokinetics issues.

[{"selector":"#anim-19192304-c396-47c4-9f32-9c426343599b","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

3. SAR444419, an anti-TNFa/IL-6 nanobody from Ablynx, is also being discontinued.

[{"selector":"#anim-cac13e4c-a9ff-4e3f-9965-65e67b6c9af3","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

4. Sanofi's buyout of Principia Biopharma in 2020 has experienced several setbacks.

[{"selector":"#anim-88a468c2-9aba-4599-bf4a-f7636772c6ff","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

5. A Phase III study of tolebrutinib in myasthenia gravis was stopped due to strong competition.

[{"selector":"#anim-ac6a83ee-8301-4b35-b661-4c1f70c21740","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

6. Tolebrutinib is still under Phase II and III trials for multiple sclerosis.

[{"selector":"#anim-f9799797-79ed-47d9-8aab-6d816f3015e9","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

7. Berger, Sanofi's chief medical officer, has stepped into the R&D role.

[{"selector":"#anim-bd39efa7-84fb-4ef6-a9d7-19a951308e9b","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

8. In 2018, Sanofi acquired Belgium-based Ablynx for $4.85 billion.

[{"selector":"#anim-096bb053-cece-489d-8aea-a06236d0b23e","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

9. Sanofi is also discontinuing programs for approved drugs Dupixent and Sarclisa.

[{"selector":"#anim-cc7a07da-6f04-40f0-bc31-4d20d8c18bc2","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

10. Similar to Sanofi, Novartis and Biogen are also trimming their pipelines post Q1.

[{"selector":"#anim-c9c00390-f2f6-4b09-baa1-f7068c6283ef","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-6292d107-a5a0-43a6-a1ed-9354f71167b8","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more